RAPT Therapeutics/RAPT

$8.67

-3.89%
-
1D1W1MYTD1YMAX

About RAPT Therapeutics

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, the Company develops selective small molecules that are designed to modulate the critical immune responses underlying these diseases. Its two lead drug candidates each target C-C motif chemokine receptor 4 (CCR4). Its inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells) into inflamed tissues. Its lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. In addition, RPT193 has clinical translatability in a variety of inflammatory diseases beyond atopic dermatitis (AD), including allergic asthma and chronic rhinosinusitis.

Ticker

RAPT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Brian Wong

Employees

129

Headquarters

South san francisco, United States
Website
rapt.com

RAPT Metrics

BasicAdvanced
$308.88M
Market cap
-
P/E ratio
-$2.88
EPS
0.33
Beta
-
Dividend rate

What the Analysts think about RAPT

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 8 analysts.
166.78% upside
High $48.00
Low $10.00
$8.67
Current price
$23.13
Average price target

RAPT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-31.3M
24.21%
Profit margin
0%
-

RAPT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.86%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.64
-$0.76
-$0.66
-$0.82
-
Expected
-$0.65
-$0.68
-$0.78
-$0.75
-$0.86
Surprise
-2.14%
11.76%
-15.57%
8.86%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell RAPT Therapeutics stock

Buy or sell RAPT Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing